

information base. Notable among these are that (i) dioxin is a probable human carcinogen; and (ii) impacts of dioxin exposure on human health, including enzyme induction and developmental, reproductive, or endocrine effects, may be occurring at or within an order of magnitude of average background body burdens.

It is important to note that the outside scientific community was not significantly involved in developing these conclusions. Apart from a day-and-a-half meeting with outside experts in September 1992, preparation of the risk characterization has been an in-house affair. Although much has been learned in recent years about the toxicity of dioxin and related compounds, there are still major gaps in understanding that can be filled only by additional careful scientific study. The conclusions of EPA's current risk characterization are thus heavily dependent upon many unproved assumptions and untested hypotheses that deserve careful scrutiny by the scientific community. Divergent opinions regarding these conclusions can be expected.

We strongly encourage scientists to take an active role in determining the inferences that can be drawn with scientific rigor from

the available data. Most important, we urge EPA to clearly distinguish regulatory policy from matters of scientific fact. Otherwise, the press and public will surely misinterpret the hypothetical risks presented in the re-assessment as real.

Christopher A. Bradfield, Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, IL 60611, USA; **Michael A. Gallo**, Environmental and Community Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854-5635, USA; **Thomas A. Gasiowicz**, Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA; **Raymond S. Greenberg**, School of Public Health, Emory University, Atlanta, GA 30329, USA; **William F. Greenlee**, Department of Pharmacology and Toxicology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907-1334, USA; **Joseph Margolick**, Division of Toxicological Sciences, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205, USA; **Donald R. Mattison**, University of Pittsburgh, Pittsburgh, PA 15261, USA; **Peter Munson**, Silver Spring, MD 20904, USA; **Robert A. Neal**, Center in Molecular Toxicology, Department of Biochemistry, Vanderbilt University School of Medicine, Station 17 Nashville, TN 37232, USA; **Allan B. Okey**, Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8; **David L. Olive**, Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510, USA; **Alan Poland**, McArdle Center for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53706, USA; **Arleen B. Rifkind**, Department of Phar-


macology, Cornell University Medical College, New York, NY 10021, USA; **Joseph V. Rodricks**, ENVIRON Corporation, 4350 North Fairfax Drive, Arlington, VA 22203, USA; **Karl Rozman**, Department of Pharmacology and Toxicology, University of Kansas Medical Center, Kansas City, KS 66160, USA; **Stephen H. Safe**, Department of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA; **Thomas B. Starr**, ENVIRON Corporation, 7500 Rainwater Road, Raleigh, NC 27615, USA; **Thomas R. Sutter**, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205-2179, USA.

Corrections and Clarifications

In John Travis' Research News article "Glia: The brain's other cells" (11 Nov., p. 970), work at Iowa State University was mentioned on page 971, and Philip Hayden was named as the group leader. His team was one of two working on the project. The other group, which focused on the release of glutamate by astrocytes, was led by Srdija Jeftinija. In the same article, it was stated that William Greenough organized a glia workshop at last year's neuroscience meeting. That workshop was held at the 1993 Winter Conference on Brain Research at Snowbird, Utah.

In the News article "Astronomy's optical illusion" by John Travis (21 Oct., p. 356), the name of Paul Schechter of the Massachusetts Institute of Technology was given incorrectly on page 357 as Paul "Schectman."

Monoclonal Antibodies to Rat Cell Adhesion



For research use only. Not for drug or other uses.

The purest biochemicals for research in
 ☒ Carbohydrate Chemistry ☒ Molecular Biology
 ☒ Immunology ☒ Cell Biology



SEIKAGAKU AMERICA, INC.

30 West Gude Drive, Suite 260
 Rockville, MD 20850-1161
 Tel. 301-424-0546, 1-800-237-4512
 Fax. 301-424-6961

A subsidiary of SEIKAGAKU CORPORATION Tokyo, Japan

SEIKAGAKU CORPORATION

1-5, Nihonbashi-honcho 2-chome, Chuo-ku
 Tokyo 103, Japan
 Tel. 81-3-3245-1951
 Fax. 81-3-3242-5335

"SEIKAGAKU" means "biochemistry"

Circle No. 55 on Readers' Service Card

NEW TECHNOLOGY

Quixell—a revolutionary
 new system for the
 automated selection
 and transfer of
 single cells...

**one
 cell
 at a time.**



Selected cell being drawn into Quixell's glass micropipette. All other cells remain undisturbed.



Stoelting Co. 620 Wheat Lane
 Wood Dale, IL 60191 USA
 (708) 860-9700

Circle No. 1 on Readers' Service Card